FDA reviewing Teva's Huntington's drug; Vertex hands back $3M in tax break;

@FierceBiotech: We're looking for 2015's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: What does Google's corporate shuffle mean for its biotech ambitions? Story | Follow @JohnCFierce

@DamianFierce: A wonderfully stern FDA official parses Kim Kardashian's Instagram. Warning letter | Follow @DamianFierce

> Teva ($TEVA) says that the FDA has accepted the NDA for its Huntington's drug dubbed SD-809 (deutetrabenazine). Release

> Vertex ($VRTX) worked out a deal with the City of Boston to trim its tax break by $3 million a year after failing to come through with all the new jobs it promised ahead of building a new headquarters in the Seaport District. Story

> The CRO Accelovance is adding 70 jobs in Wales. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Rehabilitation startup rolls out new muscle therapy device for leg paralysis. Story | Follow @FierceMedDev

@VarunSaxena2: Study: Device industry suffers from first-mover disadvantage due to FDA regs. Article | Follow @VarunSaxena2

@EmilyWFierce: UPDATED: Kim Kardashian Instagram post lands Duchesnay in FDA hot water. More from FiercePharmaManufacturing | Follow @EmilyWFierce

> New York startup trots out video-game like screening device for Alzheimer's. Story

> Helius enters clinical trial of its PoNS brain stimulation device to treat traumatic brain injury. More

> Wearable pain relief device set to hit store shelves due to distribution alliance. Report

Pharma News

@FiercePharma: Real-time data can put slow drug launches into the fast lane, researcher says. More from FiercePharmaMarketing | Follow @FiercePharma

@EricPFierce: GSK stops production at North Carolina plant after Legionella bacteria found in cooling tower. News | Follow @EricPFierce

@CarlyHFierce: Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi. FiercePharmaMarketing story | Follow @CarlyHFierce

> GSK site closed after Legionella bacteria detected in cooling tower. More

> Roche scores Accutane victory with reversal of $25M verdict. Story

> Daiichi clot-buster wins a NICE green light, but still faces an uphill track. Article

Biotech Research News

> Vitamin B3 pathway may lead to new obesity drugs. Item

> MGH study pinpoints a genetic trigger for heart valve disorder. Report

> UBC team stakes a claim on a newly discovered 'obesity gene.' More

> Overstimulating oncogene family SRC shows promise against cancer. Story

> TSRI researchers say enzyme may work as an anti-smoking treatment. Article

Diagnostics News

> VisionGate sets sights on FDA approval for noninvasive lung cancer Dx. Editor's corner

> Biocept partners with UC Irvine on liquid biopsy research. News

> Response Genetics throws in towel, sells out to Cancer Genetics for $14M. More

> Roche selects Hawaii's Diagnostic Laboratory Services for molecular diagnostics project. Report

> Invitae dials up testing guidance amid positive Q2 numbers. Article

Pharma Marketing News

> Legionnaires' discovery prompts GlaxoSmithKline to idle NC plant. Item

> Real-time data can put slow drug launches into the fast lane, researcher says. Report

> Abbott, Novartis tap into #ILookLikeAnEngineer social media movement. More

> Kim Kardashian Instagram post lands Duchesnay in FDA hot water. Story

> Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.